文献速递免疫规划

在无细胞百日咳疫苗中添加TLR7激动剂可增强小鼠模型中的Th1和Th17应答及保护性免疫

Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.
PubMed 文献 · Vaccine · 2017-08-18

在多个发达国家尽管疫苗覆盖率广泛,百日咳仍出现复发,原因可能包括流行菌株抗原变异、监测和诊断工具变化以及无细胞百日咳疫苗与全细胞疫苗保护力的差异。小鼠模型研究显示,将基于Toll样受体7激动剂(TLR7a)的新型佐剂吸附于氢氧化铝后配制无细胞百日咳疫苗,可增强百日咳博德特菌特异性Th1和Th17应答及血清IgG2a/b抗体,并增强疫苗对百日咳博德特菌气溶胶攻击的保护效力,保护力与全细胞疫苗相当。

要点

  • 无细胞百日咳疫苗配以铝-TLR7a佐剂可增强Th1和Th17应答及血清IgG2a/b抗体。
  • 铝-TLR7a佐剂增强无细胞百日咳疫苗对百日咳博德特菌气溶胶攻击的保护效力。
  • 铝-TLR7a佐剂配制的无细胞百日咳疫苗保护力与全细胞疫苗相当。

核心结论

  • 铝-TLR7a是下一代百日咳疫苗临床开发中有前景的佐剂。

研究设计与样本

  • 小鼠模型研究,比较无细胞百日咳疫苗单独配制铝佐剂与配以铝-TLR7a佐剂后的免疫应答和保护效力。

主要发现

  • 无细胞百日咳疫苗配以铝-TLR7a佐剂可增强百日咳博德特菌特异性Th1和Th17应答及血清IgG2a/b抗体,其功能能力强于单独铝佐剂配制的无细胞百日咳疫苗所诱导的抗体。
  • 添加TLR7a增强无细胞百日咳疫苗对百日咳博德特菌气溶胶攻击的保护效力,保护力与全细胞疫苗相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A resurgence of whooping cough (pertussis) has been observed in recent years in a number of developed countries, despite widespread vaccine coverage. Although the exact reasons of the recurrence of pertussis are not clear, there are a number of potential causes, like antigenic variation in the circulating strains of Bordetella pertussis, changes in surveillance and diagnostic tools, and potential differences in protection afforded by current acellular pertussis (aP) vaccines compared to more reactogenic whole cell (wP) vaccines, which they replaced. Studies in animal models have shown that induction of cellular as well as humoral immune responses are key to conferring effective and long lasting protection against B. pertussis. wP vaccines induce robust Th1/Th17 responses, which are associated with good protection against lung infection. In contrast, aP vaccines induce mixed Th2/Th17 responses. One research option is to modify current aP vaccines with the intention of inducing protective T cell responses, without compromising on their low reactogenicity profile. Here we found that formulation of an aP vaccine with a novel adjuvant based on a Toll-like receptor 7 agonist (TLR7a) adsorbed to aluminum hydroxide (alum) enhanced B. pertussis-specific Th1 and Th17 responses and serum IgG2a/b antibodies, which had greater functional capacity than those induced by aP formulated with alum alone. Furthermore, addition of a TLR7a enhanced the protective efficacy of the aP vaccine against B. pertussis aerosol challenge; protection was comparable to that of a wP vaccine. These findings suggest that alum-TLR7a is a promising adjuvant for clinical development of next generation pertussis vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Misiak A, Leuzzi R, Allen AC, et al. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. Vaccine. 2017. PMID: 28823618. doi:10.1016/j.vaccine.2017.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。